This report contains the collective views of an international group of experts and does not necessarily represent the decisions or the stated policy of the World Health Organization

WHO Technical Report Series

852

ONCHOCERCIASIS AND ITS CONTROL

Report of a WHO Expert Committee on Onchocerciasis Control



World Health Organization

Geneva 1995

WHO Library Cataloguing in Publication Data

WHO Expert Committee on Onchocerciasis Control Onchocerciasis and its control: report of a WHO Expert Committee on Onchocerciasis Control.

(WHO technical report series; 852)

1.Onchocerciasis - prevention & control 1.Title II.Series

ISBN 92 4 120852 X (NLM Classification: WC 885) ISSN 0512-3054

The World Health Organization welcomes requests for permission to reproduce or translate its publications, in part or in full. Applications and enquiries should be addressed to the Office of Publications, World Health Organization, Geneva, Switzerland, which will be glad to provide the latest information on any changes made to the text, plans for new editions, and reprints and translations already available.

© World Health Organization 1995

Publications of the World Health Organization enjoy copyright protection in accordance with the provisions of Protocol 2 of the Universal Copyright Convention. All rights reserved.

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

Contents

1.	Introduction	1
2.	 The parasite 2.1 Habitat of adult worms 2.2 Mating, insemination and fertilization 2.3 Distribution of developmental stages in female worms 2.4 Microfilarial release from female worms 2.5 Duration of reproductive life span 2.6 Correlation between adult worm loads, microfilarial loads and exposure to infective larvae 2.7 Suggestions for further study 	50 22 22 55 66
3.	The vectors 3.1 The Simulium damnosum complex 3.2 The Simulium neavei group 3.3 Vector capacity and transmission in West Africa 3.4 Vector species in the Americas 3.5 Vector capacity and transmission in the Americas 3.6 Suggestions for further study	6 11 11 12 13
4.	The disease 4.1 Clinical signs and symptoms 4.2 Ocular signs and symptoms 4.3 Immune responses and pathogenesis 4.4 Clinical and immunological changes following treatment with ivermectin 4.5 Suggestions for further study	15 15 18 20 22 24
5.	Geographical distribution, epidemiology and public health importance 5.1 Introduction 5.2 Numbers of cases 5.3 Geographical distribution and trends 5.4 Epidemiology 5.5 Public health importance 5.6 Suggestions for further study	25 25 25 30 37 38 39
6.	Social and economic impact 6.1 Socioeconomic consequences 6.2 Community knowledge, beliefs and attitudes 6.3 Socioeconomic benefits of control in the OCP area 6.4 Cost-benefit analysis of OCP operations 6.5 Socioeconomic consequences in the Americas 6.6 Suggestions for further study	40 40 40 41 42 44
7.	Diagnosis and surveillance 7.1 Clinical diagnosis 7.2 The Mazzotti test 7.3 Parasitological diagnosis 7.4 Use of DNA probes for surveillance 7.5 Recent advances in immunodiagnosis for surveillance 7.6 Suggestions for further study	45 45 46 46 47 48 50

8.	Treatment	50
	8.1 Introduction8.2 Ivermectin8.3 Suramin	50 50 52
	8.4 Amocarzine	54
	8.5 Benzimidazoles	56
	8.6 Diethylcarbamazine	56
	8.7 Evaluation of the effectiveness of chemotherapeutic agents8.8 Suggestions for further study	56 57
9.	Control: objective, strategies and epidemiological modelling 9.1 Objective	57 57
	9.2 Factors affecting control strategies	58
	9.3 Strategies	60
	9.4 Use of epidemiological models to predict trends in the prevalence of infection	62
	9.5 Suggestions for further study	63
10.	Control through vector control 10.1 Operational aspects and impact of insecticide treatments	63 64
	10.2 Resistance and its management by the rotation of insecticides	67 68
	10.3 Impact of larviciding on the aquatic environment 10.4 Environmental management	69
	10.5 Integrated control	69
11.	. Control through chemotherapy	70 70
	11.1 Introduction 11.2 Organizations and groups stimulating and supporting the distribution	70
	of ivermectin	70
	11.3 Methods of distribution	72
	11.4 Identification of priority areas for large-scale ivermectin treatment	75
	11.5 Suggestion for further study	78
12.	. Monitoring and evaluation of control	78
	12.1 Monitoring large-scale chemotherapy	78
	12.2 Entomological evaluation of the impact of vector control	79 80
	12.3 Evaluation of control 12.4 Suggestions for further study	83
	12.4 Suggestions for further study	00
13	Sustainability of ivermectin distribution programmes 13.1 Introduction	84 84
	13.2 The parties concerned	84
	13.3 Establishment of sustainable programmes	85
	13.4 Cost-effectiveness	86
		0.7
14	. Training	87 88
	14.1 Types of training 14.2 Training materials	89
	14.3 Implications of devolution in the OCP area	89
15	i. Conclusions	90
16	s. Recommendations	91

Acknowledgements	92
References	93
Annex A clinical classification and grading system for recording the cutaneous changes of onchocerciasis	97



WHO Expert Committee on Onchocerciasis Control

Geneva, 29 November-6 December 1993

Members

- Professor A. O. Abiose, Medical Director, National Eye Centre, Kaduna, Nigeria (Rapporteur)
- Dr K. Awadzi, Director, Onchocerciasis Chemotherapy Research Centre, Hohoe Hospital, Hohoe, Ghana (*Vice-Chairman*)
- Professor E.W. Cupp, Professor of Medical/Veterinary Entomology, University of Arizona, Tucson, AZ, USA
- Dr B. O. L. Duke, Medical Director, River Blindness Foundation, Lancaster, England (Chairman)
- Dr E. I. I. Gemade, Mectizan Project Manager, Zone C, National Onchocerciasis Control Programme, Kaduna, Nigeria
- Dr E.A. Ottesen, Head, Clinical Parasitology Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA (*Rapporteur*)
- Dr I. Petralanda, Director, Amazon Centre for Investigation and Control of Tropical Diseases, Puerto Ayacucho, Amazonas Federal Territory, Venezuela
- Dr J.-B. Roungou, Director, Preventive Medicine and Control of Major Endemic Diseases, Bangui, Central African Republic
- Dr H. Schulz-Key, Professor, Institute for Tropical Medicine, University of Tübingen, Tübingen, Germany
- Dr N. Weiss, Head, Department of Medical Parasitology, Swiss Tropical Institute, Basel, Switzerland

Secretariat

- Dr D. A. T. Baldry, Cessy, Gex, France (Consultant)
- Dr K. Y. Dadzie, Programme for the Prevention of Blindness, WHO, Geneva, Switzerland
- Dr C. P. Ramachandran, Chief, Filariasis Control, Division of Control of Tropical Diseases, WHO, Geneva, Switzerland (Secretary)
- Dr J. H. F. Remme, UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases, WHO, Geneva, Switzerland

Abbreviations

The following abbreviations are used in this report:

FAO Food and Agriculture Organization of the United Nations

L₃ infective larvae of *Onchocerca volvulus*

L₄ fourth-stage larvae of *Onchocerca volvulus* that have

developed from L₃ larvae

NGO nongovernmental organization

OCP Onchocerciasis Control Programme in West Africa
OEPA Onchocerciasis Elimination Program in the Americas

UNDP United Nations Development Programme

UNICEF United Nations Children's Fund WHO World Health Organization



